BioSpace News Archive

POINT Biopharma Global Inc. (NASDAQ: PNT), and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energie Nucléaire, today announced a technology license agreement for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added lutetium-177 (n.c.a. Lu-177) production program.

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, today announced that management will participate in The Benchmark Company 10th Annual Discovery One-on-One Investor Conference.

Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company seeking to improve lives through the curative potential of gene therapies, today announced the recent appointment of Su Zhang, M.B.A., as the Chief Financial Officer (CFO).

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following investor conferences.

Oramed Pharmaceuticals Inc. announced today that its common stock will be added to the MSCI USA Small Cap Index effective Tuesday, November 30th at the close of market.

Pasithea Therapeutics Corp. today announced that it has entered into securities purchase agreements with certain institutional investors to purchase 8.68 million shares of its common stock and warrants to purchase 8.68 million shares of its common stock.

Praxis Precision Medicines , Inc. today announced that management will participate in a fireside chat at Piper Sandler’s 33rd Annual Virtual Healthcare Conference on Thursday, December 2, 2021 at 10:30 a.m. ET.

The success of FDA cleared Transpara AI has been marked by a record number of peer reviewed papers and well over 2,000,000 mammograms being read by this unique system.

Hemogenyx Pharmaceuticals PLC Announces Convertible Loans Repayment

Biotechnology startup Tiamat Sciences today announced its $3 million seed financing round led by Silicon Valley venture capital firm True Ventures with participation from Social Impact Capital and Cantos.